Normosang (Human Hemin)

Human Hemin supplies heme directly to the body, which feeds back to inhibit aminolevulinic acid synthase, the first enzyme in the heme biosynthetic pathway. By down‑regulating this enzyme, the drug reduces the synthesis and accumulation of upstream porphyrin precursors such as ALA and PBG, thereby preventing their toxic effects during an acute porphyria episode.

The specific dose of Normosang is determined by the prescribing clinician based on the severity of the attack, patient weight and clinical response. The product is supplied as a 250 mg lyophilized vial that is reconstituted to a concentration of 3 mg/mL and administered intravenously under medical supervision.

Safety data for Human Hemin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Normosang, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative to Normosang is heme arginate (Panhematin), another intravenous heme preparation. Both provide exogenous heme to inhibit ALA synthase, but formulation differences exist: Normosang is supplied as a lyophilized powder reconstituted to 3 mg/mL, whereas heme arginate is a ready‑to‑use solution. Clinical efficacy is comparable, while choice may depend on local availability, handling preferences and regulatory status.

Normosang must be stored at 2‑8 °C (refrigerated). The vial should be kept in its original packaging, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used promptly according to the prescribing information and any remaining product discarded if not used within the recommended time frame.

Normosang is administered intravenously after reconstitution. The 250 mg vial is diluted with a suitable sterile diluent to achieve a concentration of 3 mg/mL. The infusion is given under medical supervision, typically over a period of 30‑60 minutes, with monitoring of vital signs and any infusion‑related reactions throughout the procedure.

The most serious adverse events associated with Normosang include anaphylactic or severe allergic reactions, hemolysis (particularly in patients with G6PD deficiency), and acute renal failure. Prompt recognition of symptoms such as difficulty breathing, sudden drop in blood pressure, dark urine, or rapid decline in kidney function is essential, and immediate medical intervention should be initiated.

Normosang should be avoided in individuals with known hypersensitivity to human hemin or any excipients in the formulation. Patients with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency are also contraindicated because of the risk of hemolysis. Use is not recommended without confirmed diagnosis of an acute porphyria attack.